IN 001 - InnoRNA
Alternative Names: IN-001 InnoRNALatest Information Update: 30 Aug 2024
At a glance
- Originator InnoRNA
- Class RNA vaccines; Varicella vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Herpes zoster
Most Recent Events
- 05 Jul 2024 Phase-I clinical trials in Herpes zoster (Prevention) in Australia (IM) (NCT06375512)
- 05 Jul 2024 Phase-I clinical trials in Herpes zoster (Prevention) in USA (IM) (NCT06375512)
- 25 Apr 2024 InnoRNA (Shenzhen Shenxin Biotechnology) plans a phase I trial for Herpes zoster (Prevention) in USA and Australia (IM, Injection) in July 2024 (NCT06375512)